NanoDetection Technology™ and Oligomerix™ Announce Exclusive Global Licensing Agreement for Breakthrough Neurodegenerative Diagnostic Antibodies
NanoDetection Technology, Incorporated (NDT) and Oligomerix, Inc. today announced the execution of an exclusive worldwide license agreement. Under the terms of the agreement, NanoDetection has secured exclusive rights to develop and commercialize diagnostic tests utilizing a proprietary panel of nine Tau antibodies discovered by Oligomerix, Inc. and widely recognized for their scientific importance in neurodegenerative disease research. Oligomerix retains rights to therapeutic applications of the antibody panel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602591343/en/
Quantifying Protein State Transitions
The licensed antibody portfolio represents a significant advancement in the characterization of Alzheimer’s disease and other Tau-related pathologies. These highly specialized reagents enable differentiation among distinct Tau species, including cleavage-specific and conformationally altered forms located within the protein filament core.
